Structured Review

Millipore eh tbb
Representative HPLC-radiochromatograms of [ 14 C]-radioactivity extracted from feces collected between 12 and 24 h from female SD rats administered <t>EH-TBB.</t> (A) [ 14 C]-EH-TBB and TBBA standards; (B) 0.1 <t>µmol/kg</t> (IV); (C) 0.1 µmol/kg (oral); (D) 1 µmol/kg (oral); (E) 10 µmol/kg (oral); (F) 100 µmol/kg (oral).
Eh Tbb, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eh tbb/product/Millipore
Average 90 stars, based on 12 article reviews
Price from $9.99 to $1999.99
eh tbb - by Bioz Stars, 2020-09
90/100 stars

Images

1) Product Images from "Disposition of the Emerging Brominated Flame Retardant, 2-Ethylhexyl 2,3,4,5-Tetrabromobenzoate, in Female SD Rats and Male B6C3F1 Mice: Effects of Dose, Route, and Repeated Administration"

Article Title: Disposition of the Emerging Brominated Flame Retardant, 2-Ethylhexyl 2,3,4,5-Tetrabromobenzoate, in Female SD Rats and Male B6C3F1 Mice: Effects of Dose, Route, and Repeated Administration

Journal: Toxicological Sciences

doi: 10.1093/toxsci/kfw176

Representative HPLC-radiochromatograms of [ 14 C]-radioactivity extracted from feces collected between 12 and 24 h from female SD rats administered EH-TBB. (A) [ 14 C]-EH-TBB and TBBA standards; (B) 0.1 µmol/kg (IV); (C) 0.1 µmol/kg (oral); (D) 1 µmol/kg (oral); (E) 10 µmol/kg (oral); (F) 100 µmol/kg (oral).
Figure Legend Snippet: Representative HPLC-radiochromatograms of [ 14 C]-radioactivity extracted from feces collected between 12 and 24 h from female SD rats administered EH-TBB. (A) [ 14 C]-EH-TBB and TBBA standards; (B) 0.1 µmol/kg (IV); (C) 0.1 µmol/kg (oral); (D) 1 µmol/kg (oral); (E) 10 µmol/kg (oral); (F) 100 µmol/kg (oral).

Techniques Used: High Performance Liquid Chromatography, Radioactivity

Representative HPLC-radiochromatograms of [ 14 C]-radioactivity in urine collected between 12 and 24 h from female SD rats administered EH-TBB. (A) [ 14 C]-EH-TBB and TBBA standards; (B) 0.1 µmol/kg (IV); (C) 0.1 µmol/kg (oral); (D) 1 µmol/kg (oral); (E) 10 µmol/kg (oral); (F) 100 µmol/kg (oral).
Figure Legend Snippet: Representative HPLC-radiochromatograms of [ 14 C]-radioactivity in urine collected between 12 and 24 h from female SD rats administered EH-TBB. (A) [ 14 C]-EH-TBB and TBBA standards; (B) 0.1 µmol/kg (IV); (C) 0.1 µmol/kg (oral); (D) 1 µmol/kg (oral); (E) 10 µmol/kg (oral); (F) 100 µmol/kg (oral).

Techniques Used: High Performance Liquid Chromatography, Radioactivity

Representative mass spectra of extracted urine following EH-TBB (100 µmol/kg) administration by gavage to female SD rats. (A) Total ion chromatogram for extracted urine after UPLC separation. (B) Full-scale mass spectrum for peak eluting between 9.1and 9.3 min, m / z of 489.46 Da is consistent with the mass of a TBBA-glycine [M–H] − ion. (C) Full-scale mass spectrum for peak eluting between 9.6 and 9.8 min, m / z of 514.56 Da is consistent with the TBBA-sulfate [M–H] − . (D) Full-scale mass spectrum for peak eluting between 10.7 and 11.2 min, m / z of 481.23 Da is consistent with the TBBA [M + H] − ion with a formic acid adduct ( m / z = 481.23 Da); a mass consistent with at TBBA dimer ( m / z ).
Figure Legend Snippet: Representative mass spectra of extracted urine following EH-TBB (100 µmol/kg) administration by gavage to female SD rats. (A) Total ion chromatogram for extracted urine after UPLC separation. (B) Full-scale mass spectrum for peak eluting between 9.1and 9.3 min, m / z of 489.46 Da is consistent with the mass of a TBBA-glycine [M–H] − ion. (C) Full-scale mass spectrum for peak eluting between 9.6 and 9.8 min, m / z of 514.56 Da is consistent with the TBBA-sulfate [M–H] − . (D) Full-scale mass spectrum for peak eluting between 10.7 and 11.2 min, m / z of 481.23 Da is consistent with the TBBA [M + H] − ion with a formic acid adduct ( m / z = 481.23 Da); a mass consistent with at TBBA dimer ( m / z ).

Techniques Used:

2) Product Images from "Disposition of the emerging brominated flame retardant, bis(2-ethylhexyl) tetrabromophthalate, in female Sprague Dawley rats: effects of dose, route, and repeated administration"

Article Title: Disposition of the emerging brominated flame retardant, bis(2-ethylhexyl) tetrabromophthalate, in female Sprague Dawley rats: effects of dose, route, and repeated administration

Journal: Xenobiotica; the fate of foreign compounds in biological systems

doi: 10.1080/00498254.2016.1174793

Representative mass spectra of bile following BEH-TEBP (0.1 μmol/kg) administration by IV to female SD rats. A: Total ion chromatogram for bile after UPLC separation. B: Full-scale extracted ion chromatograms for peak eluting at 2.226 min, m/z of 296.6 Da is consistent with that of a doubly charged TBMEHP [M+H] − ion (inset, lower abundance singly charged TBMEHP [M+H] − ion). C: Full-scale extracted ion chromatograms for peak eluting at 2.259 min m/z of 288.7 Da is consistent with that of a doubly charged demethylated TBMEHP [M+H] − ion (inset, lower abundance singly charged demethylated TBMEHP [M+H] − ion).
Figure Legend Snippet: Representative mass spectra of bile following BEH-TEBP (0.1 μmol/kg) administration by IV to female SD rats. A: Total ion chromatogram for bile after UPLC separation. B: Full-scale extracted ion chromatograms for peak eluting at 2.226 min, m/z of 296.6 Da is consistent with that of a doubly charged TBMEHP [M+H] − ion (inset, lower abundance singly charged TBMEHP [M+H] − ion). C: Full-scale extracted ion chromatograms for peak eluting at 2.259 min m/z of 288.7 Da is consistent with that of a doubly charged demethylated TBMEHP [M+H] − ion (inset, lower abundance singly charged demethylated TBMEHP [M+H] − ion).

Techniques Used:

Representative HPLC-radiochromatograms of [ 14 C]-radioactivity in excreta bile following BEH-TEBP administration (0.1 μmol/kg) to female SD rats. A: [ 14 C]-BEH-TEBP standard. B: [ 14 C]-radioactivity in fecal extracts after oral administration. C: [ 14 C]-radioactivity in bile after BEH-TEBP IV administration. D: [ 14 C]-radioactivity in fecal extracts after BEH-TEBP IV administration.
Figure Legend Snippet: Representative HPLC-radiochromatograms of [ 14 C]-radioactivity in excreta bile following BEH-TEBP administration (0.1 μmol/kg) to female SD rats. A: [ 14 C]-BEH-TEBP standard. B: [ 14 C]-radioactivity in fecal extracts after oral administration. C: [ 14 C]-radioactivity in bile after BEH-TEBP IV administration. D: [ 14 C]-radioactivity in fecal extracts after BEH-TEBP IV administration.

Techniques Used: High Performance Liquid Chromatography, Radioactivity

Chemical structure of (A) BEH-TEBP and (B) TBMEHP; *[ 14 C]-radiolabel on a single carbonyl carbon.
Figure Legend Snippet: Chemical structure of (A) BEH-TEBP and (B) TBMEHP; *[ 14 C]-radiolabel on a single carbonyl carbon.

Techniques Used:

Related Articles

Concentration Assay:

Article Title: Adenosinergic Signaling Alters Natural Killer Cell Functional Responses
Article Snippet: .. For the cytotoxicity assays, ADO deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, Sigma-Aldrich) was used at a concentration of 30 μM. .. Flow cytometry For flow cytometric analysis, cells were washed with FACS buffer (1X PBS, 5% FBS) and then stained for 30 min at 4°C with select antibodies CD56 (Pe-Cy5.5, Clone: CMSSB/APC, Clone:5.1H11), CD3 (Pe-Cy7, Clone: UCHT1), CD73 (APC, Clone: 82), CD16 (APC, Clone: B73.1), NKp30 (BV711, Clone: p30-15), NKG2D (PE, Clone: 1D11), IFN-γ (Percp-Cy5.5, Clone: B27), pS6 (V450, Clone: N7-548), pSTAT5 (PE, Clone: 47), and DNAM (PE, Clone: DX11) (eBioscience, BD, or BioLegend).

Incubation:

Article Title: Extracellular 2?,3?-cAMP-adenosine pathway in proximal tubular, thick ascending limb, and collecting duct epithelial cells
Article Snippet: .. Cells were washed twice with HEPES-buffered Hanks balanced salt solution and then incubated for 1 h in 0.5 ml of Dulbecco's phosphate-buffered saline with HEPES (25 mmol/l) and NaHCO3 (13 mmol/l) in the presence and absence of 2′,3′-cAMP, 5′-AMP, 3′-AMP, or 2′-AMP with or without α,β-methylene-adenosine-5′-diphosphate (AMPCP; selective inhibitor of CD73) , 3-isobutyl-1-methylxanthine (IBMX; broad spectrum phosphodiesterase inhibitor) , 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX; ecto-phosphodiesterase inhibitor) ( , , ), all from Sigma (St. Louis, MO). .. After 1-h incubation, the medium was collected, heated for 90 s at 100°C to denature enzymes, and then frozen at −80°C until assayed by liquid chromatography-tandem mass spectrometery (LC-MS/MS).

other:

Article Title: Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y12 signaling with MRS2395
Article Snippet: MRS2395 [2,2-Dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester], adenosine diphosphate (ADP), wortmannin, thrombin and all other chemicals and reagents were purchased from Sigma-Aldrich (St Louis, MO, USA) or previously mentioned sources unless specified otherwise.

Article Title: The reconstituted Escherichia coli MsbA protein displays lipid flippase activity
Article Snippet: Materials ATP, AMP-PNP (adenosine 5′-[β,γ-imido]triphosphate), DTE (dithioerythritol), lipid A, NBD–GlcCer (NBD–C6 -glucosylceramide), NBD–LacCer (NBD–C6 -lactosylceramide), OG (octyl-β-D -glucopyranoside), RaLPS, ReLPS, sodium dithionite, Vi (sodium orthovanadate), Triton X-100, BeSO4 4H2 O (beryllium sulfate tetrahydrate) and AlCl3 were purchased from Sigma–Aldrich.

Purification:

Article Title: Insights into how nucleotide supplements enhance the peroxidase-mimicking DNAzyme activity of the G-quadruplex/hemin system
Article Snippet: .. Hemin, ABTS, 3,3′,5,5′-tetramethylbenzidine (TMB), adenosine diphosphate (ADP), nucleoside triphosphate (NTP) (N = A, T, C, G) were purchased from Sigma-Aldrich, and adenosine 5'-(β,γ-imido)triphosphate (ADP-N-P) from Jena Bioscience; all the chemicals were used without further purification. ..

MTT Assay:

Article Title: Inhibitory effects of extracellular adenosine triphosphate on growth of esophageal carcinoma cells
Article Snippet: .. ATP, ADO, acridine orange (AO), ethidium bromide (EB), 3-(4,5-dimethyiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma. .. RNase, SDS, proteinase K, trypsin and agarose were from Sino-American Biotec Co., RPMI 1640 medium was from GIBCO, and fetal bovine serum (FBS) was from Hangzhou Sijiqing Biotec Co. ATP and ADO were dissolved in sterile PBS, and stored at -20°C.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Millipore teniposide
    <t>Teniposide</t> activated cGAS/STING-dependent IFN-I signaling in tumor cells. ( A ) B16 cells were treated with teniposide or DMSO for 24 hours; then γH2AX expression was detected by immunofluorescence staining. Scale bar: 10 μm. ( B ) B16 cells were treated as in A ; then the expression levels of IFN-β, CCL5, and CXCL10 were measured by qPCR. ( C ) Cells were treated as in A ; then the supernatant levels of CCL5 and CXCL10 were measured by ELISA. ( D ) B16/WT and B16/STING KO cells were treated with teniposide or DMSO for 24 hours; then the levels of mRNA and protein expression of CCL5 and CXLC10 were measured by qPCR and ELISA, respectively. ( E and F ) B16-OVA/WT, B16-OVA/cGAS-KO and B16-OVA/STING-KO cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z+BMDCs for an additional 24 hours. T cell activation was measured by supernatant IL-2 levels and surface expression of CD69. Protein expression of cGAS or STING was measured by Western blot. Actin was used as a loading control. ( G – I ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z in the presence of WT or Ifnar –/– BMDCs for an additional 24 hours, after which LacZ activity and the supernatant levels of IL-2 and IFN-γ were determined. Data shown in A are representative of 1 of 3 independent experiments. Data shown in B – I are represented as mean ± SD of 3 independent experiment. ** P
    Teniposide, supplied by Millipore, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/teniposide/product/Millipore
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    teniposide - by Bioz Stars, 2020-09
    94/100 stars
      Buy from Supplier

    93
    Millipore cremophor
    <t>Teniposide</t> activated cGAS/STING-dependent IFN-I signaling in tumor cells. ( A ) B16 cells were treated with teniposide or DMSO for 24 hours; then γH2AX expression was detected by immunofluorescence staining. Scale bar: 10 μm. ( B ) B16 cells were treated as in A ; then the expression levels of IFN-β, CCL5, and CXCL10 were measured by qPCR. ( C ) Cells were treated as in A ; then the supernatant levels of CCL5 and CXCL10 were measured by ELISA. ( D ) B16/WT and B16/STING KO cells were treated with teniposide or DMSO for 24 hours; then the levels of mRNA and protein expression of CCL5 and CXLC10 were measured by qPCR and ELISA, respectively. ( E and F ) B16-OVA/WT, B16-OVA/cGAS-KO and B16-OVA/STING-KO cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z+BMDCs for an additional 24 hours. T cell activation was measured by supernatant IL-2 levels and surface expression of CD69. Protein expression of cGAS or STING was measured by Western blot. Actin was used as a loading control. ( G – I ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z in the presence of WT or Ifnar –/– BMDCs for an additional 24 hours, after which LacZ activity and the supernatant levels of IL-2 and IFN-γ were determined. Data shown in A are representative of 1 of 3 independent experiments. Data shown in B – I are represented as mean ± SD of 3 independent experiment. ** P
    Cremophor, supplied by Millipore, used in various techniques. Bioz Stars score: 93/100, based on 49 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cremophor/product/Millipore
    Average 93 stars, based on 49 article reviews
    Price from $9.99 to $1999.99
    cremophor - by Bioz Stars, 2020-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Teniposide activated cGAS/STING-dependent IFN-I signaling in tumor cells. ( A ) B16 cells were treated with teniposide or DMSO for 24 hours; then γH2AX expression was detected by immunofluorescence staining. Scale bar: 10 μm. ( B ) B16 cells were treated as in A ; then the expression levels of IFN-β, CCL5, and CXCL10 were measured by qPCR. ( C ) Cells were treated as in A ; then the supernatant levels of CCL5 and CXCL10 were measured by ELISA. ( D ) B16/WT and B16/STING KO cells were treated with teniposide or DMSO for 24 hours; then the levels of mRNA and protein expression of CCL5 and CXLC10 were measured by qPCR and ELISA, respectively. ( E and F ) B16-OVA/WT, B16-OVA/cGAS-KO and B16-OVA/STING-KO cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z+BMDCs for an additional 24 hours. T cell activation was measured by supernatant IL-2 levels and surface expression of CD69. Protein expression of cGAS or STING was measured by Western blot. Actin was used as a loading control. ( G – I ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z in the presence of WT or Ifnar –/– BMDCs for an additional 24 hours, after which LacZ activity and the supernatant levels of IL-2 and IFN-γ were determined. Data shown in A are representative of 1 of 3 independent experiments. Data shown in B – I are represented as mean ± SD of 3 independent experiment. ** P

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Teniposide activated cGAS/STING-dependent IFN-I signaling in tumor cells. ( A ) B16 cells were treated with teniposide or DMSO for 24 hours; then γH2AX expression was detected by immunofluorescence staining. Scale bar: 10 μm. ( B ) B16 cells were treated as in A ; then the expression levels of IFN-β, CCL5, and CXCL10 were measured by qPCR. ( C ) Cells were treated as in A ; then the supernatant levels of CCL5 and CXCL10 were measured by ELISA. ( D ) B16/WT and B16/STING KO cells were treated with teniposide or DMSO for 24 hours; then the levels of mRNA and protein expression of CCL5 and CXLC10 were measured by qPCR and ELISA, respectively. ( E and F ) B16-OVA/WT, B16-OVA/cGAS-KO and B16-OVA/STING-KO cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z+BMDCs for an additional 24 hours. T cell activation was measured by supernatant IL-2 levels and surface expression of CD69. Protein expression of cGAS or STING was measured by Western blot. Actin was used as a loading control. ( G – I ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with B3Z in the presence of WT or Ifnar –/– BMDCs for an additional 24 hours, after which LacZ activity and the supernatant levels of IL-2 and IFN-γ were determined. Data shown in A are representative of 1 of 3 independent experiments. Data shown in B – I are represented as mean ± SD of 3 independent experiment. ** P

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques: Expressing, Immunofluorescence, Staining, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Activation Assay, Western Blot, Activity Assay

    Teniposide enhanced expression of antigen-presenting machinery molecules on tumor cells. ( A and B ) B16, MC38, PDAC, and CT26 cells were treated with teniposide or DMSO for 20 hours, and the surface expression of MHC-I and MHC-II was determined by FACS. ( C ) Cells were treated as in A , and the expression of antigen-presenting machinery genes were measured by qPCR. Data in A and B are shown as the representative results of 3 repeated experiments. Data in C are shown as mean ± SD of 3 independent experiments. * P

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Teniposide enhanced expression of antigen-presenting machinery molecules on tumor cells. ( A and B ) B16, MC38, PDAC, and CT26 cells were treated with teniposide or DMSO for 20 hours, and the surface expression of MHC-I and MHC-II was determined by FACS. ( C ) Cells were treated as in A , and the expression of antigen-presenting machinery genes were measured by qPCR. Data in A and B are shown as the representative results of 3 repeated experiments. Data in C are shown as mean ± SD of 3 independent experiments. * P

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques: Expressing, FACS, Real-time Polymerase Chain Reaction

    Teniposide induced ICD of tumor cells. ( A ) MC38 (HMGB1-Gluc) and CT26 (HMGB1-Gluc) cells were treated with increasing doses of teniposide for 20 hours, and HMGB1-Gluc luciferase activity was measured. ( B and C ) CT26 cells were treated with teniposide or DMSO for 20 hours, and cell apoptosis ( B ) and surface expression of CRT( C ) were detected by FACS. ( D ) CT26 tumor cells were pretreated with teniposide, etoposide, or freeze-thawed, followed by subcutaneous inoculation into BALB/c mice as a vaccine ( n = 8 for control group with no tumor cell vaccine administered, teniposide group, and freeze-thawed group; n = 5 for etoposide group). After 8 days, mice were rechallenged with live CT26 cells. Shown are the percentages of tumor-free mice 30 days after rechallenge. Data in A – C are shown as mean ± SD of 3 independent experiments. ** P

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Teniposide induced ICD of tumor cells. ( A ) MC38 (HMGB1-Gluc) and CT26 (HMGB1-Gluc) cells were treated with increasing doses of teniposide for 20 hours, and HMGB1-Gluc luciferase activity was measured. ( B and C ) CT26 cells were treated with teniposide or DMSO for 20 hours, and cell apoptosis ( B ) and surface expression of CRT( C ) were detected by FACS. ( D ) CT26 tumor cells were pretreated with teniposide, etoposide, or freeze-thawed, followed by subcutaneous inoculation into BALB/c mice as a vaccine ( n = 8 for control group with no tumor cell vaccine administered, teniposide group, and freeze-thawed group; n = 5 for etoposide group). After 8 days, mice were rechallenged with live CT26 cells. Shown are the percentages of tumor-free mice 30 days after rechallenge. Data in A – C are shown as mean ± SD of 3 independent experiments. ** P

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques: Luciferase, Activity Assay, Expressing, FACS, Mouse Assay

    Combined drug-screening assays identified teniposide as an ICD drug.

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Combined drug-screening assays identified teniposide as an ICD drug.

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques:

    Teniposide-treated tumor cells induced T cell activation and DC maturation. ( A – D ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with BMDC and B3Z cells for an additional 24 hours, after which B3Z activation was measured by LacZ activity, IL-2 production, and IFN-γ production ( A – C ) and CD69 expression ( D ). ( E – G ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultures with BMDC and OT-I cells for an additional 24 hours or 48 hours, after which OT-I activation was measured by secretion of IL-2 and IFN-γ and surface expression of CD69. ( H – M ) B16-OVA cells were treated with DMSO or indicated concentration of teniposide for 16 hours, then cocultured with BMDCs for an additional 24 hours, after which surface expression of CD80, CD86, CD40, MHC-II, MHC-I, and MHC-I–SIINFEKL on CD11c + DCs was determined by FACS. Data in A – M are shown as mean ± SD of 3 independent experiments. * P

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Teniposide-treated tumor cells induced T cell activation and DC maturation. ( A – D ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultured with BMDC and B3Z cells for an additional 24 hours, after which B3Z activation was measured by LacZ activity, IL-2 production, and IFN-γ production ( A – C ) and CD69 expression ( D ). ( E – G ) B16-OVA cells were treated with teniposide or DMSO for 16 hours, then cocultures with BMDC and OT-I cells for an additional 24 hours or 48 hours, after which OT-I activation was measured by secretion of IL-2 and IFN-γ and surface expression of CD69. ( H – M ) B16-OVA cells were treated with DMSO or indicated concentration of teniposide for 16 hours, then cocultured with BMDCs for an additional 24 hours, after which surface expression of CD80, CD86, CD40, MHC-II, MHC-I, and MHC-I–SIINFEKL on CD11c + DCs was determined by FACS. Data in A – M are shown as mean ± SD of 3 independent experiments. * P

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques: Activation Assay, Activity Assay, Expressing, Concentration Assay, FACS

    Teniposide induced immune cell infiltration and potentiated efficacy of anti-PD1 therapy in a CT26 mouse tumor model. ( A – N ) Mice with established CT26 tumors were treated with teniposide or vehicle on days 6 and 7 (10 mg/kg, i.p.). Tumors were isolated on day 10, and tumor-infiltrating immune cells were analyzed by flow cytometry. Data are representative of 1 of 2 independent experiments. Shown are tumor volume ( A ), tumor weight ( B ), intratumoral T cells ( C ), numbers of tumor-infiltrating CD8 + T cells ( D ), CD4 + T cells ( E ), and expression of activation marker CD69 ( F and G ) and effector molecules IFN-γ, GZMB, and TNF-α ( H – J ) in CD8 + T cells. ( K – N ) Surface expression levels of MHC-I, MHC-II, CD40, and CD86 on CD11c + cells were determined by FACS. n = 4 mice per group. ( O ) Mice were injected with CD8 or CD4 depletion antibody on days 3, 6, and 9 after CT26 tumor inoculation, followed by teniposide treatment on days 7 and 8 (10 mg/kg, i.p.). Tumor volume is shown as mean ± SD. n = 5 per group. ( P ) Mice with established CT26 tumors were treated with teniposide, anti-PD1, or teniposide in combination with anti-PD1 at indicated time points. Tumor volume was shown as mean ± SD. n = 7 per group. ( Q ) Mice were inoculated with CT26-shSCR (scramble shRNA as control) or CT26-shSTING cells and then treated with indicated drugs. Tumor volume is shown as mean ± SD. n = 5 per group. * P

    Journal: The Journal of Clinical Investigation

    Article Title: cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity

    doi: 10.1172/JCI127471

    Figure Lengend Snippet: Teniposide induced immune cell infiltration and potentiated efficacy of anti-PD1 therapy in a CT26 mouse tumor model. ( A – N ) Mice with established CT26 tumors were treated with teniposide or vehicle on days 6 and 7 (10 mg/kg, i.p.). Tumors were isolated on day 10, and tumor-infiltrating immune cells were analyzed by flow cytometry. Data are representative of 1 of 2 independent experiments. Shown are tumor volume ( A ), tumor weight ( B ), intratumoral T cells ( C ), numbers of tumor-infiltrating CD8 + T cells ( D ), CD4 + T cells ( E ), and expression of activation marker CD69 ( F and G ) and effector molecules IFN-γ, GZMB, and TNF-α ( H – J ) in CD8 + T cells. ( K – N ) Surface expression levels of MHC-I, MHC-II, CD40, and CD86 on CD11c + cells were determined by FACS. n = 4 mice per group. ( O ) Mice were injected with CD8 or CD4 depletion antibody on days 3, 6, and 9 after CT26 tumor inoculation, followed by teniposide treatment on days 7 and 8 (10 mg/kg, i.p.). Tumor volume is shown as mean ± SD. n = 5 per group. ( P ) Mice with established CT26 tumors were treated with teniposide, anti-PD1, or teniposide in combination with anti-PD1 at indicated time points. Tumor volume was shown as mean ± SD. n = 7 per group. ( Q ) Mice were inoculated with CT26-shSCR (scramble shRNA as control) or CT26-shSTING cells and then treated with indicated drugs. Tumor volume is shown as mean ± SD. n = 5 per group. * P

    Article Snippet: Tumors were allowed to grow for 6 or 7 days, and teniposide (dissolved in 10% Cremophor EL in PBS, MilliporeSigma) or vehicle was administered by i.p. injection (10 mg/kg) twice at indicated time points.

    Techniques: Mouse Assay, Isolation, Flow Cytometry, Cytometry, Expressing, Activation Assay, Marker, FACS, Injection, shRNA